Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.77 |
| ▸ | DRD4 | P21917 | 14/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7558681 | 0.88 | DRD4 (0.81) | DRD2DRD4MEN1ADRA1DADRA1A | |
| SCHEMBL7553491 | 0.87 | DRD2 (0.83) | DRD2DRD4MEN1ADRA1DADRA1A | |
| SCHEMBL7551427 | 0.87 | DRD2 (0.83) | DRD2DRD4MEN1ADRA1DADRA1A | |
| SCHEMBL7552763 | 0.87 | DRD4 (1.00) | DRD2DRD4MEN1ADRA1DADRA1A | |
| SCHEMBL7555293 | 0.84 | DRD4 (0.82) | DRD2DRD4MEN1ADRA1DADRA1A | |
| SCHEMBL7555333 | 0.84 | DRD2 (0.78) | DRD2DRD4MEN1ADRA1DADRA1A | |
| SCHEMBL8208943 | 0.76 | DRD2 (0.65) | DRD2DRD4NOTUM | |
| SCHEMBL9052703 | 0.71 | SIGMAR1 (0.63) | DRD2DRD4L3MBTL1HIF1AEPAS1 | |
| SCHEMBL7550236 | 0.71 | NOTUM (0.69) | DRD2DRD4MEN1KMT2ANOTUM | |
| SCHEMBL14438076 | 0.69 | L3MBTL1 (0.74) | L3MBTL1HIF1AEPAS1FAAHSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | NEUROGEN CORPORATION. | 2002-09-12 | — | — | US | disclosed |
| US-6355644-B1 | NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | GABRP, GABBR1, GABARAP | DRD2 30/4885DRD4 57/4885L3MBTL1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.